Brian M. Culley

Brian M. Culley

Chief Executive OfficeratLineage Cell Therapeutics· In proxies 2022–2025

Pay in FY2025-17% from the year before

Brian M. Culley was paid $2.1M in FY2025 (Dec), down 17%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Lineage Cell Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Lineage Cell TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrNo stock prices for these years
  2. Orphagen Pharmaceuticals, Inc.Public company · 5 yr
    • Director2017 – 2022 · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?